Cartography Biosciences Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
60
- Latest Deal Type
-
Later Stage VC
- Investors
-
20
Cartography Biosciences General Information
Description
Developer of antibody-based oncology therapies designed to target tumors with high precision. The company offers ATLAS and SUMMIT discovery platforms powered by integrated healthy tissue and tumor profiling data with AI-driven biological insights, enabling cancer patients and oncology researchers to access therapies with greater tumor selectivity and improved treatment impact.
Contact Information
Website
www.cartography.bioCorporate Office
- 230 East Grand Avenue
- 2nd Floor, Suite 250
- South San Francisco, CA 94080
- United States
Corporate Office
- 230 East Grand Avenue
- 2nd Floor, Suite 250
- South San Francisco, CA 94080
- United States
Cartography Biosciences Timeline
Cartography Biosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC | 06-May-2026 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series B) | 22-May-2025 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 19-Jul-2022 | $57M | $63M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 23-Nov-2021 | $6M | $6M | Completed | Startup |
Cartography Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-1 | ||||||||
| Series B | ||||||||
| Series A | 12,954,354 | $0.000100 | 6% | $3.9 | $3.9 | 1x | $3.9 | 12.02% |
| Seed | 7,200,288 | $0.000100 | 6% | $0.83 | $0.83 | 1x | $0.83 | 6.68% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Cartography Biosciences Comparisons
Industry
Financing
Details
Cartography Biosciences Competitors (101)
One of Cartography Biosciences’s 101 competitors is Dendreon, a Formerly VC-backed company based in Seal Beach, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Dendreon | Formerly VC-backed | Seal Beach, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Virogin Biotech | Venture Capital-Backed | Richmond, Canada | ||||
| Geneos Therapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA |
Cartography Biosciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Cartography Biosciences Patents
Cartography Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026025085-A2 | Ly6g6d multispecific binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof | Pending | 25-Jul-2024 | ||
| WO-2026025085-A3 | Ly6g6d multispecific binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof | Pending | 25-Jul-2024 | ||
| AU-2025263569-A1 | Ly6g6d binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof | Pending | 24-Apr-2024 | ||
| US-20250361298-A1 | Ly6g6d binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof | Pending | 24-Apr-2024 | ||
| WO-2025226970-A2 | Ly6g6d binding proteins, nucleic acids encoding such proteins, and methods for the preparation and use thereof | Pending | 24-Apr-2024 | C07K16/2803 |
Cartography Biosciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cartography Biosciences Investors (20)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Samsung Biologics | Corporation | Minority | ||
| Amgen Ventures | Corporate Venture Capital | Minority | ||
| Finchley Healthcare Ventures | Venture Capital | Minority | ||
| Global BioAccess Fund | Venture Capital | Minority | ||
| Hawktail | Venture Capital | Minority |
Cartography Biosciences FAQs
-
When was Cartography Biosciences founded?
Cartography Biosciences was founded in 2020.
-
Where is Cartography Biosciences headquartered?
Cartography Biosciences is headquartered in South San Francisco, CA.
-
What is the size of Cartography Biosciences?
Cartography Biosciences has 60 total employees.
-
What industry is Cartography Biosciences in?
Cartography Biosciences’s primary industry is Drug Discovery.
-
Is Cartography Biosciences a private or public company?
Cartography Biosciences is a Private company.
-
What is Cartography Biosciences’s current revenue?
The current revenue for Cartography Biosciences is .
-
How much funding has Cartography Biosciences raised over time?
Cartography Biosciences has raised $143M.
-
Who are Cartography Biosciences’s investors?
Samsung Biologics, Amgen Ventures, Finchley Healthcare Ventures, Global BioAccess Fund, and Hawktail are 5 of 20 investors who have invested in Cartography Biosciences.
-
Who are Cartography Biosciences’s competitors?
Dendreon, Adaptimmune Therapeutics, Virogin Biotech, Geneos Therapeutics, and Poseida Therapeutics are some of the 101 competitors of Cartography Biosciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
